Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261 is registered in ClinicalTrials.gov with Nancy Lin, MD as lead sponsor.

NCT NCT06176261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06176261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Lead sponsor
Nancy Lin, MD
Phase
Phase 2
Overall status
Recruiting
Start date
January 8, 2024
Completion date
January 1, 2029
Enrollment
58 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer female, er positive breast cancer, er-negative breast cancer, her2 negative breast carcinoma, her2-negative breast cancer, metastatic triple-negative breast carcinoma